Question special
Chief Resident

Since in this trial the medication showed mortality in addition to other benefits in patients while on GDMT including device therapy when appropriate these results are quite impressive.
However one can argue where in the GDMT will this medication fit especially considering the fact that sacubitril/valsartan (approved for over 4 yrs now) is highly under utilized to date in real world. (Even in this trial only 10-11 % pts were on it).
I would like to know authors insight into it.
Thank you.